INSPECS Group plc (AIM:SPEC)
London · Delayed Price · Currency is GBP · Price in GBX 82.50
-1.50 (-1.79%)
Apr 17, 2026, 8:00 AM GMT
INSPECS Group Market Cap
INSPECS Group has a market cap or net worth of 85.4 million as of April 17, 2026. Its market cap has increased by 66.34% in one year.
Market Cap
85.40M
Enterprise Value
121.38M
Revenue
195.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
82.50
Market Cap Chart
Since February 27, 2020, INSPECS Group's market cap has decreased from 137.95M to 85.40M, a decrease of -38.09%. That is a compound annual growth rate of -7.52%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 15, 2026 | 84.90M | 16.78% |
| Dec 31, 2025 | 72.70M | 57.14% |
| Dec 31, 2024 | 46.26M | -45.83% |
| Dec 29, 2023 | 85.40M | 95.35% |
| Dec 30, 2022 | 43.72M | -88.33% |
| Dec 31, 2021 | 374.78M | 12.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Feb 27, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 229.02B |
| GSK plc | 84.81B |
| Haleon | 31.43B |
| Smith & Nephew | 10.78B |
| EKF Diagnostics Holdings | 105.90M |
| Shield Therapeutics | 98.29M |
| Bioventix | 94.05M |
| Faron Pharmaceuticals Oy | 88.58M |